MAPT and Alzheimer disease: Therefore, we consider that the reduction in the Aβ levels due to apicidin treatment (in mice aged 9–12 months) cannot reduce the level of phosphorylated tau in older APP/PS1 mice because tau phosphorylation probably occurs in an Aβ‐independent manner in later phases of AD.